Influence of haemodialysis on the in vitro mitogenic function and interferon-gamma production of the CD4- and CD8-positive T-lymphocytes in patients undergoing chronic heamodialysis

Completed

• Conditions: immunity; resistance; 10002252; 10029149

• Registration Number: NL-OMON33618
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 12 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

group A - renal failure, haemodialysis
group B - renal failure, peritoneal dialysis
group C - renal failure, no dialysis

Exclusion Criteria

group D - renal failure and/or immunocompromising condition or immunosuppressive medication

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To identify the possible differences (intrapersonal variability) in the<br /><br>proliferative function of:<br /><br>- T-lymphocytes generally (using the phytohemaglutinine tube)<br /><br>- TB-specific lymphocytes (using the Quantiferon-GIT test)<br /><br>- CMV-specific lymphocytes (using the Quantiferon-CMV test)<br /><br>- HB-specific lymphocytes (using the Quantiferon-HB)<br /><br>between the blood samples which were drawn before, during and after the same<br /><br>hemodialysis.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. differences in the proportion of patients with indeterminate test result in<br /><br>the positive controle tube (phytohaemaglutinine) in the haemodialysis, PD,<br /><br>non-haemodialysis renal failure and control groups<br /><br><br /><br>2. differences in the proportion of patients with positive Quantiferon-CMV test<br /><br>in the hemodialysis, PD, non-HD renal failure and control groups<br /><br><br /><br>3. differences in the proportion of patients with positive Quantiferon-HB test<br /><br>in the hemodialysis, PD, non-HD renal failure and control groups<br /><br><br /><br>4. differences in the proliferative capacity measured as the amount of produced<br /><br>IFN-&gamma; in the positive controle tube between the group of patients with<br /><br>hemodialysis, PD, non-HD renal failure and control group</p><br>